It does seem like a typical early-stage biotech play. They're showing promising Phase 2 data, have registered trials, hyped it up at JPM for funding, and have clear next steps into Phase 3. If those trials pan out (especially the muscle preservation part), it could actually shake up the oral obesity treatment scene.
They have listings on ClinicalTrials.gov. It's not just sitting around doing nothing. There are details on study designs, completion estimates into 2026, and the sponsor info. They presented Phase 2 info at conferences like ADA and ENDO, and claim to have significant weight loss *without* muscle loss thanks to the IGF-1 part. And there were announcements about Phase 3 programs focusing on durable weight loss and lean-mass preservation.
